Humacyte, Inc. (NASDAQ:HUMA – Free Report) – Analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Humacyte in a note issued to investors on Thursday, May 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.14) for the quarter. The consensus estimate for Humacyte’s current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Humacyte’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at ($0.10) EPS.
Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $1.46 million. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.
Check Out Our Latest Report on HUMA
Humacyte Stock Performance
NASDAQ HUMA opened at $0.90 on Tuesday. The stock has a 50-day simple moving average of $0.85 and a two-hundred day simple moving average of $1.05. The firm has a market capitalization of $199.46 million, a P/E ratio of -1.58 and a beta of 2.31. Humacyte has a fifty-two week low of $0.55 and a fifty-two week high of $2.93. The company has a debt-to-equity ratio of 5.46, a quick ratio of 3.32 and a current ratio of 3.93.
Hedge Funds Weigh In On Humacyte
Institutional investors and hedge funds have recently modified their holdings of the business. Imprint Wealth LLC purchased a new stake in Humacyte during the 3rd quarter worth approximately $33,000. Prudential Financial Inc. purchased a new stake in Humacyte during the 2nd quarter worth approximately $28,000. Atom Investors LP purchased a new stake in Humacyte during the 4th quarter worth approximately $25,000. Sei Investments Co. purchased a new stake in Humacyte during the 1st quarter worth approximately $56,000. Finally, Private Advisor Group LLC increased its stake in Humacyte by 48.3% during the 1st quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after buying an additional 271,222 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.
Key Headlines Impacting Humacyte
Here are the key news stories impacting Humacyte this week:
- Neutral Sentiment: HC Wainwright released updated EPS estimates across multiple periods, including Q2 2026 at -$0.14, Q3 2026 at -$0.10, Q4 2026 at -$0.10, FY2026 at -$0.43, Q1 2027 at -$0.09, Q2 2027 at -$0.10, Q3 2027 at -$0.07, FY2027 at -$0.31, and FY2028 at -$0.10, signaling continued losses ahead.
- Neutral Sentiment: The firm’s FY2028 estimate was cut to -$0.10 from -$0.06, and FY2027 was reduced to -$0.31 from -$0.27, suggesting a softer long-term profitability outlook. HC Wainwright Predicts Humacyte’s Q4 Earnings (NASDAQ:HUMA)
- Neutral Sentiment: HC Wainwright’s FY2026 estimate was also lowered to -$0.43 from -$0.37, reinforcing expectations that Humacyte will remain unprofitable in the near term.
Humacyte Company Profile
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Featured Stories
- Five stocks we like better than Humacyte
- Why Trump’s Amazon Stock Sale May Not Matter at All
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
